Table 2 Demographics and disease-related data relation to apolipoprotein C3
From: Apolipoprotein C-III in patients with systemic lupus erythematosus
Apo C3, mg/dl | ||
|---|---|---|
Beta coef. (95% CI), p | ||
Age, years | 0.04 (0.02–0.05) | < 0.001 |
Women | 0.19 (− 0.70–0.91) | 0.80 |
Body mass index, kg/m2 | 0.04 (0.02–0.08) | 0.004 |
Abdominal circumference, cm | 0.02 (0.01–0.04) | < 0.001 |
Systolic blood pressure, mmHg | 0.01 (0.00–0.02) | 0.003 |
Diastolic blood pressure, mmHg | − 0.00 (− 0.00–0.00) | 0.63 |
Cardiovascular comorbidity | ||
Smoking | 0.11 (− 0.70–0.91) | 0.80 |
Diabetes | - | |
Hypertension | 0.73 (0.40–1.07) | < 0.001 |
Obesity | 0.51 (0.14–0.88) | 0.008 |
Statins | 0.57 (0.18–0.95) | 0.004 |
Aspirin | 0.01 (− 0.37–0.40) | 0.94 |
Antihypertensive treatment | 0.72 (0.38–1.06) | < 0.001 |
Analytical and lipid profile | ||
CRP, mg/dl | 0.01 (− 0.00–0.02) | 0.055 |
Cholesterol × 10, mg/dl | − 0.01 (− 0.06–0.02) | 0.39 |
Triglycerides × 10, mg/dl | 0.03 (0.01–0.06) | 0.002 |
HDL cholesterol × 10, mg/dl | − 0.16 (− 0.25 to − 0.07) | < 0.001 |
LDL cholesterol × 10, mg/dl | − 0.01 (− 0.07–0.04) | 0.72 |
LDL:HDL cholesterol ratio | 0.30 (− 0.08–0.53) | 0.009 |
Non-HDL cholesterol × 10, mg/dl | − 0.02 (− 0.06–0.02) | 0.36 |
Apolipoprotein A1 × 10, mg/dl | − 0.05 (− 010– -0.01) | 0.026 |
Apolipoprotein B × 10, mg/dl | − 0.00 (− 0.07–0.06) | 0.94 |
Apo B: A1 ratio | 0.70 (− 0.33–1.72) | 0.18 |
Lipoprotein (a) × 10, mg/dl | − 0.00 (− 0.02–0.01) | 0.60 |
Atherogenic index | 0.24 (0.08–0.39) | 0.003 |
SLE-related data | ||
Disease duration, years | 0.02 (0.00–0.04) | 0.048 |
SLICC | 0.14 (0.06–0.23) | 0.001 |
SLICC ≥ 1 | 0.46 (0.07–0.85) | 0.020 |
Katz index | 0.10 (0.01–0.19) | 0.030 |
SLEDAI | 0.02 (− 0.01–0.06) | 0.19 |
SLEDAI categories | ||
No activity | ref | |
Mild and moderate | 0.39 (0.03–0.75) | 0.035 |
High or very high | 0.69 (0.02–1.37) | 0.045 |
Auto-antibody profile | ||
Anti-DNA positive | − 0.11 (− 0.56–0.34) | 0.63 |
ENA positive | − 0.12 (− 0.74–0.50) | 0.70 |
Anti-Ro | − 0.17 (− 0.56–0.23) | 0.40 |
Anti-La | − 0.27 (− 0.75–0.21) | 0.26 |
Anti-RNP | 0.09 (− 0.31–0.49) | 0.66 |
Anti-Sm | − 0.34 (− 0.87–0.18) | 0.19 |
Any antiphospholipid autoantibodies, n (%) | ||
Lupus anticoagulant | 0.16 (− 0.28–0.61) | 0.47 |
ACA IgM | − 0.03 (− 0.59–0.54) | 0.93 |
ACA IgG | 0.22 (− 0.25–0.70) | 0.35 |
Anti-beta2 glycoprotein IgM | − 0.03 (− 0.73–0.67) | 0.93 |
Anti-beta2 glycoprotein IgG | 0.40 (− 0.14–0.93) | 0.14 |
C3 × 10, mg/dl | − 0.00 (− 0.7–0.05) | 0.77 |
C4 × 10, mg/dl | 0.09 (− 0.15–0.33) | 0.47 |
Current prednisone | 0.23 (− 0.11–0.56) | 0.19 |
Prednisone, mg/day | 0.09 (0.01–0.16) | 0.023 |
DMARDs | − 0.36 (− 0.77–0.04) | 0.080 |
Hydroxychloroquine | − 0.33 (− 0.69–0.03) | 0.072 |
Hydroxychloroquine, mg/day × 10 | − 0.01 (− 0.03–0.006) | 0.18 |
Methotrexate | − 0.03 (− 0..56–0..50) | 0.92 |
Mycophenolate mofetil | − 0.23 (− 0.83–0.37) | 0.45 |
Azathioprine | 0.37 (− 0.12–0.86) | 0.13 |
Rituximab | − 0.47 (− 1.39–0.46) | 0.32 |
Belimumab | 0.29 (− 1.01–1.59) | 0.66 |